SEARCH    

A Tabulated Summary of the FDG PET Literature

Contents:

References

  1. AAssar OS, Fischbein NJ, Caputo GR, et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999;210:177 - 181.
  2. Abdel-Nabi H, Abou-Zied MM, Doerr RJ. Preoperative evaluation of patients with suspected liver metastases with positron emission tomography with F - 18 FDG . J Nucl Med 1999;40:241P.
  3. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206:755 - 760.
  4. Achten E, Santens P, Boon P, et al. Single-voxel proton MR spectroscopy and positron emission tomography for lateralization of refractory temporal lobe epilepsy. Am J Neuroradiol 1998;19:1 - 8.
  5. Acland KM, O´Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol 2000;42:606 - 611.
  6. Adams S, Baum R, Stuckensen T, Bitter K, Hör G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255 - 1260.
  7. Adler L, Crowe J, al-Kaisi N, Sunshine J. Evaluation of breast masses and axillary lymph nodes with Figure F-18 2 deoxy-2-fluoro-D-glucose PET. Radiology. 1993;187:743 - 750.
  8. Adler L, Faulhaber P, Schnur K, Al-Kasai N, Shenk R. Axillary lymph node metastases: screening with Figure F-182 deoxy-2-D-glucose (FDG) PET. Radiology 1997;203:323 - 327.
  9. Adler LP, Bloom AD. Positron emission tomography of thyroid masses. Thyroid 1993;3:195 - 200.
  10. Akimura T, Yeh HS, Mantil JC, Privitera MD, Gartner M, Tomsick TA. Cerebral metabolism of the remote area after epilepsy surgery. Neurol Medico-Chirurg 1999;39:16 - 27.
  11. Al-Sugair AS, Coleman RE. Relative diagnostic efficacy of F-18 FDG PET and bone scintigraphy for detection of osseous metastases in primary or secondary lung cancer . J Nucl Med 1999;40:20P.
  12. Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1999;53:808 - 811.
  13. Albes JM, Lietzenmayer R, Schott U, Schülen E, Wehrmann M, Ziemer G. Improvement of non-small-cell lung cancer staging by means of positron emission tomography. Thoracic Cardiovasc Surgeon 1999;47:42 - 47.
  14. Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 2000;41:1010 - 1015.
  15. Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schäfers M, Schober O. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 1998;383:160 - 163.
  16. Amthauer H, Hosten N, Mueller-York A, et al. Whole body FDG-PET before laser-induced thermo-therapy (LITT) in patients with hepatic metastases of colorectal cancer . J Nucl Med 2000;41:35P.
  17. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-Figure F-18fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996;200:135 - 141.
  18. Austin JR, Wong FC, Kim EE. Positron emission tomography in the detection of residual laryngeal carcinoma. Otolaryngol Head Neck Surg 1995;113:404 - 407.
  19. Avril N, Dose J, Jänicke F, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848 - 1857.
  20. Avril N, Schelling M, Naehrig J, et al. Monitoring primary chemotherapy in advanced breast cancer using FDG-PET . J Nucl Med 2000;41:112P - 113P.
  21. Bachor R, Kocher F, Gropengiesser F, Reske SN, Hautmann RE. Positron emission tomography: introduction of a new imaging technique for urological tumors and initial clinical results [in German]. Urologe Ausgabe A 1995;34:138 - 142.
  22. Bachor R, Kotzerke J, Gottfried HW, Braendle E, Reske SN, Hautmann R. Positron emission tomography (PET) for diagnosis of renal cell carcinoma (RCC) [in German]. Urologe Ausgabe A 1996;35:146 - 150.
  23. Bachor R, Kotzerke J, Reske SN, Hautmann R. Lymph node staging for urinary bladder carcinoma with positron emission tomography (PET) [in German]. Urologe Ausgabe A 1999;38:46 - 50.
  24. Bader JB, Samnick S, Schaefer A, et al. Contribution of nuclear medicine to the diagnosis of recurrent brain tumors and cerebral radionecrosis [in German]. Radiologe 1998;38:924 - 929.
  25. Bader JB, Siebert S, Schaefer A, et al. Diagnostic efficiency in the detection of brain tumor recurrence at follow-up by 123I alpha-methyltyrosine-SPECT and 18FDG-PET . J Nucl Med 1997;38:239P.
  26. Baehre MH, Markert U, Meller B, et al. Oncologic information provided by immunoscintigraphy with 99mTc Fab´ fragments compared with (18F)FDG PET in colorectal cancer . J Nucl Med 2000;41:141P.
  27. Baer F, Voth E, Deutsch H. Predictive value of low-dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of left ventricular function after successful revascularization. J Am Coll Cardiol 1996;28:60 - 69.
  28. Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncologica (Stockholm) 1999;38:799 - 804.
  29. Bangerter M, Moog F, Buchman I, et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography FDG-PET for accurate staging of Hodgkin´s disease. Ann Oncol 1998;9:1117 - 1122.
  30. Bares R, Dohmen B, Cremerius U, Fass J, Teusch M, Buell U. Results of positron emission tomography with fluorine-18-labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma [in German]. Radiologe 1996;36:435 - 440.
  31. Bares R, Galonska P, Dempke W, Handt S, Büll U, Osieka R. Somatostatin receptor scintigraphy in malignant lymphoma: first results and comparison with glucose metabolism measured by positron emission tomography. Horm Metab Res. 1993;27(suppl):56 - 58.
  32. Bares R, Klever P, Hauptmann S, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994;192:79 - 86.
  33. Bares R, Klever P, Hellwig D, et al. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results. Nucl Med Commun 1993;14:596 - 601.
  34. Barrington SF, Koutroumanidis M, Agathonikou A, et al. Clinical value of "ictal" FDG-positron emission tomography and the routine use of simultaneous scalp EEG studies in patients with intractable partial epilepsies. Epilepsia 1998;39:753 - 766.
  35. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931 - 938.
  36. Baum RP, Schmuecking M, Plichta K, et al. Staging of non-small cell lung cancer (NSCLC): is PET really clinically important or just a research tool ? J Nucl Med 2000;41:293P - 294P.
  37. Beets G, Pennickx F, Schiepers C, et al. Clinical value of whole-body positron emission tomography with [18F] fluorodeoxyglucose in recurrent colorectal cancer. Br J. Surg. 1994;81:1666 - 1670.
  38. Bellon JR, Mankoff DA, Eubank WB, et al. Evaluation of the internal mammary (IM) lymph node (LN) chain by PET in locally advanced breast cancer (LABC) . J Nucl Med 2000;41:145P.
  39. Benchaou M, Lehmann W, Slosman DO, et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol 1996;116:332 - 335.
  40. Bender H, Bangard N, Metten N, et al. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. Hybridoma 1999;18:87 - 91.
  41. Bender H, Kirst J, Palmedo H, et al. Value of 18-fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997;17:1687 - 1692.
  42. Berlangieri SU, Brizel DM, Scher RL, et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck 1994;16:340 - 346.
  43. Bernstein V, Jones A, Mankoff DA, Davis N. Assessment of internal mammary lymph nodes by fluorodeoxyglucose positron emission tomography (FDG-PET) in medial hemisphere breast cancer . J Nucl Med 2000;41:289P.
  44. Berry WAC, Molloy PT, Alavi A, Vaughan SN. Neuroimaging in the evaluation of suspected brain tumor recurrence in the pediatric population, the critical role of fluorodeoxyglucose (18-FDG) positron emission tomography (PET) studies . J Nucl Med 1997;38:12P - 13P.
  45. Beuthien-Baumann B, Bredow J, Eckelt U, Franke WG, Hlawitschka M, Neise E. Diagnostic value of 18F-FDG PET in detecting carcinoma of the oral mucosa in comparison with MRI, CT, and ultrasound (US) . J Nucl Med. 2000;41:301P.
  46. Bischoff HG, Knopp MV, Rimac A, Manegold C, Drings P, Van Kaick G. Chemotherapy response monitoring with FDG positron emission tomography of patients with small cell lung cancer . Ann Hematol 1996;73:A99.
  47. Bleckmann C, Dose J, Bohuslavizki KH, et al. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer [see comments]. J Nucl Med 1999;40:2021 - 2024.
  48. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma [see comments]. Arch Dermatol 1995;131:1394 - 1398.
  49. Block M, Patterson G, Sundaresan R, et al. Improvement in staging of esophageal cancer with addition of positron emission tomography. Ann Thorac Surg 1997;64:770 - 776.
  50. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 1993;114:728 - 735.
  51. Blum DE, Ehsan T, Dungan D, Karis JP, Fisher RS. Bilateral temporal hypometabolism in epilepsy. Epilepsia 1998;39:651 - 659.
  52. Bohdiewicz PJ, Scott GC, Juni JE, et al. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations. Clin Nucl Med. 1995;20:230 - 236.
  53. Bohuslavizki KH, de Wit M, Buchert R, et al. Post-treatment 18F-FDG-PET as predictor for disease-free survival in Hodgkin´s lymphoma . J Nucl Med 2000;41:275P.
  54. Bohuslavizki KH, Klutmann S, Kröger S, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000;41:816 - 822.
  55. Bohuslavizki KH, Klutmann S, Neuber K, et al. Correlation of 18F FDG-PET and histological findings in patients with malignant melanoma . J Nucl Med 2000;41:302P.
  56. Bombardieri E, Crippa F, Agresti R, et al. FDG-PET in the assessment of axillary metastases in breast cancer. Clinical application and economic implications . J Nucl Med 1998;39:254P.
  57. Bongers V, Terhaard CJ, van Isselt JW, Hordijk GJ, van Rijk PP. Dual-head FDG-PET for the detection of recurrent laryngeal cancer compared with histopathological biopsy results and minimally 1-year clinical follow-up . J Nucl Med 2000;41:287P.
  58. Böni R, Böni RA, Steinert H, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995;132:556 - 562.
  59. Both SA, Schaeffer U, Schlenger KH, et al. 18F FDG-PET in clinical assessment of primary uterine cervical carcinoma: detection and correlation with tumor oxygen partial pressure . J Nucl Med 2000;41:116P.
  60. Braams J, Pruim J, Freling N, et al. Detection of lymph node metastases of squamous cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995;36:211 - 216.
  61. Braams JW, Pruim J, Kole AC, et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997;26:112 - 115.
  62. Brandt-Mainz K, Müller SP, Görges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Euro J Nucl Med 2000;27:490 - 496.
  63. Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 1999;14:1376 - 1380.
  64. Bury T, Dowlati A, Paulus P, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996;9:410 - 414.
  65. Bury T, Paulus P, Dowlati A, et al. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J 1996;9:2560 - 2564.
  66. Cambier JPR, Flamen P, Maes A, Van Cutsem E, Lerut T, Mortelmans L. FDG-PET for staging recurrent esophageal cancer (EC) . J Nucl Med 2000;41:32P.
  67. Caputo GR, Budinger T, Price D, Schreck C, Hawkins R. Evaluation of prostate cancer using high-resolution FDG PET imaging . J Nucl Med 1997;38:128P.
  68. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340 - 3346.
  69. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994;53:331 - 338.
  70. Chaiken L, Rege S, Hoh C, et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys 1993;27:455 - 464.
  71. Cheon G, Chung J, So Y, et al. Diagnostic accuracy of F-18 FDG-PET in the assessment of post-therapeutic recurrence of head and neck cancer. Clin Positron Imaging 1999;2:197 - 204.
  72. Chierichetti F, Rubello D, Pedrazzoli S, et al. FDG PET role in differential diagnosis of pancreatic and peri-pancreatic masses . J Nucl Med 1997;38:51P.
  73. Chin R Jr, Ward R, Keyes JW, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995;152:2090 - 2096.
  74. Chisin R, Klein M, Freedman N, et al. PET and lymphoscintigraphic evaluation of malignant melanomas: the Hadassah Hospital experience . Clin Positron Imaging 1998;1:252.
  75. Choi JY, Lee KH, Shim YM, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 2000;41:808 - 815.
  76. Chugani HT, Shewmon DA, Peacock WJ, Shields WD, Mazziotta JC, Phelps ME. Surgical treatment of intractable neonatal-onset seizures: the role of positron emission tomography. Neurology 1988;38:1178 - 1188.
  77. Chung JK, So Y, Lee JS, et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan [see comments]. J Nucl Med 1999;40:986 - 992.
  78. Collins BT, Gardner LJ, Verma AK, Lowe VJ, Dunphy FR, Boyd JH. Correlation of fine needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography in the assessment of locally recurrent and metastatic head and neck neoplasia. Acta Cytol 1998;42:1325 - 1329.
  79. Conti P, Durski J, Bacqai F, Grafton S, Singer P. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999;9:797 - 804.
  80. Cortes-Blanco A, Meyer PT, Martinez-Lazaro R, Desiderio LM, Molloy PT, Alavi AA. Discrepant performance of FDG-PET and magnetic resonance imaging (MRI) and spectroscopy (MRS) for the detection of brain tumor recurrence between adults and children . J Nucl Med 2000;41:225P.
  81. Couper GW, McAteer D, Wallis F, et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998;85:1403 - 1406.
  82. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 1998;19:1055 - 1063.
  83. Cremerius U, Wildberger H, Zimny M, Jaksy G, Gunther R, Buell U. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 1999;54:900 - 904.
  84. Crespo-Jara AA, Garcia MJ, Gimenez M, et al. Skeletal metastases in lung cancer: accuracy of 18FDG-PET in correlation with bone scintigraphy . J Nucl Med 1999;40:258P.
  85. Crespo-Jara AA, Gimenez M, Villar LM, et al. Evaluation of adrenal masses in lung cancer using 18FDG PET. J Nucl Med 2000;41:293P.
  86. Crippa F, Agresti R, Donne VD, et al. The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan [in Italian]. Tumori 1997;83:542 - 543.
  87. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18 FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998;39:4 - 8.
  88. Crowe J, Adler L, Shenk R, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol. 1994;1:132 - 140.
  89. da Silva EA, Chugani DC, Muzik O, Chugani HT. Landau-Kleffner syndrome: metabolic abnormalities in temporal lobe are a common feature. J Child Neurol 1997;12:489 - 495.
  90. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325 - 329.
  91. De Reuck J, Santens P, Decoo D, et al. Positron emission tomographic study of late-onset cryptogenic symptomatic seizures. Clin Neurol Neurosurg 1995;97:208 - 212.
  92. De Winter F, Van de Wiele C, Vogelaers D, et al. FDG PET is highly accurate in the diagnosis of chronic osteomyelitis in the central skeleton . J Nucl Med 2000;41:15P.
  93. de Wit M, Bender H, Dohmen BM, et al. Germ cell tumor: staging with FDG-PET. Pilot phase of the German multicenter trial . J Nucl Med 1999;40:256P.
  94. de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997;8(suppl 1):57 - 60.
  95. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26:51 - 56.
  96. Delbeke D, Lawrence SK, Abou-Khalil BW, Blumenkopf B, Kessler RM. Postsurgical outcome of patients with uncontrolled complex partial seizures and temporal lobe hypometabolism on 18FDG-positron emission tomography. Invest Radiol 1996;31:261 - 266.
  97. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510 - 516.
  98. Delbeke D, Morgan DS, Kovalsky E, et al. 18F-fluorodeoxyglucose imaging with positron emission tomography in the follow-up of patients with lymphoma . J Nucl Med 2000;41:70P.
  99. Delbeke D, Morgan DS, Kovalsky E, et al. 18F-fluorodeoxyglucose imaging with positron emission tomography for initial staging of Hodgkin´s disease and lymphoma . J Nucl Med 2000;41:275P.
  100. Delbeke D, Rose D, Chapman W, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999;40:1784 - 1791.
  101. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196 - 1201.
  102. Deshmukh A, Scott JA, Palmer EL, Hochberg FH, Gruber M, Fischman AJ. Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma. Clin Nucl Med 1996;21:720 - 725.
  103. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest 1993;104:997 - 1002.
  104. Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest 1995;108:441 - 446.
  105. Di Martino E, Nowak B, Krombach GA, et al. Results of pretherapeutic lymph node diagnosis in head and neck tumors. Clinical value of 18-FDG positron emission tomography (PET). Laryngo-Rhino-Otologie 2000;79:201 - 206.
  106. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:1342 - 1348.
  107. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm? Nuklearmedizin 1998;37:12 - 17.
  108. Dimitrakopoulou-Strauss A, Heichel T, Lehner B, Strauss LG. Positron emission tomography (PET) with 18F-deoxyglucose (FDG) in tumors of the skeleton system . J Nucl Med 2000;41:304P.
  109. Dimitrakopoulou-Strauss A, Schwarzbach M, Willeke F, Strauss LG. PET with FDG in soft tissue sarcomas . J Nucl Med 2000;41:303P.
  110. Dimitrakopoulou-Strauss A, Strauss LS, Goldschmidt H, Lorenz WJ, Maier-Borst W, van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995;22:434 - 442.
  111. Dittmann H, Dohmen BM, Soekler M, Kanz L, Bares R. Therapeutic relevance of FDG-PET in untreated Hodgkin´s disease and high-grade non-Hodgkin lymphoma . J Nucl Med 2000;41:71P.
  112. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130 - 140.
  113. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995;60:1348 - 1352.
  114. Duncan JD, Moss SD, Bandy DJ, et al. Use of positron emission tomography for presurgical localization of eloquent brain areas in children with seizures. Pediatr Neurosurg 1997;26:144 - 156.
  115. Eigtved A, Andersson AP, Dahlstróm K, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27:70 - 75.
  116. Engel J Jr, Henry TR, Risinger MW, et al. Presurgical evaluation for partial epilepsy: relative contributions of chronic depth-electrode recordings versus FDG-PET and scalp-sphenoidal ictal EEG. Neurology 1990;40:1670 - 1677.
  117. Ericson K, Kihlström L, Mogard J, et al. Positron emission tomography using 18F-fluorodeoxyglucose in patients with stereotactically irradiated brain metastases. Stereotact Funct Neurosurg 1996;66.(suppl 1):214 - 224.
  118. Eubank WB, Mankoff DA, Shanley TJ, et al. Assessment of mediastinal lymph node metastasis in advanced breast cancer: comparison of FDG PET with CT . J Nucl Med 1999;40:17P - 18P.
  119. Farber L, Benard F, Machtay M, et al. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope 1999;109:970 - 975.
  120. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468 - 1472.
  121. Fenchel S, Kotzerke J, Stöhr I, et al. Preoperative assessment of asymptomatic adnexal tumors by positron emission tomography and F-18 fluorodeoxyglucose. Nuklearmedizin 1999;38:101 - 107.
  122. Ferrie CD, Maisey M, Cox T, et al. Focal abnormalities detected by 18FDG PET in epileptic encephalopathies [see comments]. Arch Dis Child 1996;75:102 - 107.
  123. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil [see comments]. J Clin Oncol 1996;14:700 - 708.
  124. Finke J, Buchmann I, Bares R, et al. (F-18)-FDG-PET in primary staging of malignant lymphoma: first results of a multicenter study . J Nucl Med 1999;40:61P.
  125. Fischbein NJ, AAssar OS, Caputo GR, et al. Clinical utility of positron emission tomography with 18F-fluoro-deoxy glucose in detecting residual/recurrent squamous cell carcinoma of the head and neck [see comments]. Am J Neuroradiol 1998;19:1189 - 1196.
  126. Flamen P, Stroobants S, Dupont P, et al. Additional value of positron emission tomography (PET) with fluorodeoxyglucose (FDG) in recurrent colorectal cancer: a study in 103 patients . J Nucl Med 1998;39:134P.
  127. Flamen P, Stroobants S, Van Cutsem E, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999;17:894 - 901.
  128. Flanagan F, Dedashti F, Siegel B, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR 1997;168:417 - 424.
  129. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319 - 323.
  130. Fois A, Farnetani MA, Balestri P, et al. EEG, PET, SPET and MRI in intractable childhood epilepsies: possible surgical correlations. Child Nerv Syst 1995;11:672 - 678.
  131. Forster GJ, Kunkel M, Kutzner J, et al. Early monitoring of treatment response by (18F)FDG-PET in preoperatively irradiated advanced oral cancer . J Nucl Med 2000;41:113P.
  132. Franke C, Klapdor R, Meyerhoff K, Schauman M. 18-FDG positron emission tomography of the pancreas: diagnostic benefit in the follow-up of pancreatic carcinoma. Anticancer Res 1999;19:2437 - 2442.
  133. Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomoraphy. Gut 1995;36:771 - 777.
  134. Fröhlich A, Diederichs C, Staib L, Vogel J, Beger H, Reske S. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999;40:250 - 255.
  135. Fujii H, Yasuda S, Ide M, et al. The usefulness of breast cancer screening using 18F FDG PET . J Nucl Med 2000;41:291P.
  136. Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998;39:1002 - 1007.
  137. Gamez C, Garcia-Velloso MJ, Villar LM, et al. 18F-FDG and 11C-methionine PET for evaluation of suspected recurrent colorectal cancer . J Nucl Med 2000;41:141P.
  138. Gauthier H, Levy E, Merlet P, Thirion P, Syrota A, Meignan M. High negative predictive value of FDG-PET for assessment of progressive disease in patients with soft tissue sarcoma . J Nucl Med 1999;40:259P.
  139. Gerber B, Vanoverschelde J, Bol A. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction: implications for the pathophysiology of chronic myocardial hibernation. Circulation 1996;94:651 - 659.
  140. Gimenez M, Crespo-Jara AA, Villar L, et al. Preoperative and intraoperative uptake of 18FDG-PET in axillary metastases of breast cancer. A pathological correlation . J Nucl Med 1999;40:138P.
  141. Gliem I, Leutz M, Hellwig D, et al. Evaluation of malignancy-related pleural disease with FDG-positron emission tomography (PET) . Eur Respir J 1998;12:392S.
  142. Goldberg MA, Lee MJ, Fischman AJ, Mueller PR, Alpert NM, Thrall JH. Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging. RadioGraphics 1993;13:1047 - 1062.
  143. Grab D, Flock F, Stöhr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000;77:454 - 459.
  144. Greven KM, Keyes JW Jr, Williams DW III, McGuirt WF, Joyce WT III. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-Figure F-18fluoro-2-deoxy-D-glucose. Cancer 1999;86:114 - 118.
  145. Greven KM, Williams DW III, Keyes JW Jr, et al. Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer. Int J Radiat Oncol Biol Phys 1994;29:841 - 845.
  146. Greven KM, Williams DW III, Keyes JW Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation [see comments]. Cancer 1994;74:1355 - 1359.
  147. Grigsby PW, Dehdashti F, Elbendary AA, et al. FDG-PET evaluation of primary carcinoma of the cervix. Gynecol Oncol 1999;72:457 - 458.
  148. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420 - 1427.
  149. Gropler R, Geltman E, Sampathkurmaran K. Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomography. J Am Coll Cardiol 1993;22:1587 - 1597.
  150. Grünwald F, Kälicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547 - 1552.
  151. Grünwald F, Menzel C, Bender H, et al. Comparison of 18FDG-PET with 131I and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327 - 335.
  152. Grünwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996;23:312 - 319.
  153. Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske SN. Lymph node staging in non-small cell lung cancer: evaluation by (18F)FDG positron emission tomography (PET). Thorax 1997;52:438 - 441.
  154. Gupta NC, Bishop HA. Long-term outcome of patients with indeterminate lung nodules following management based on PET-FDG results . J Nucl Med 2000;41:76P.
  155. Gupta NC, Bishop HA, Graeber GM. Incidence and characteristics of falsely positive and negative lymph node on PET and CT in lung cancer staging . J Nucl Med 1999;40:57P.
  156. Gupta NC, Graeber G, Rogers J, Koay T, Bishop H. Relative utility of PET-FDG and CT scanning in preoperative TNM staging of lung cancer patients . J Nucl Med 1998;39:80P.
  157. Gupta NC, Graeber GM, Bishop HA, Raylman RR. Improved pre-operative staging of primary lung cancer by PET-FDG imaging . J Nucl Med 1997;38:243P - 244P.
  158. Gupta NC, Graeber GM, Bishop HA, Stephens TS. Comparative efficacy of FDG-PET in evaluation of small (less than 3 cm) and large (greater than 3 cm) pulmonary (PUL) and lymph node (LN) lesions . J Nucl Med 1997;38:79P.
  159. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET [see comments]. J Nucl Med 1996;37:943 - 948.
  160. Gupta NC, Nicholson P, Bloomfield SM. FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumors. Ann Surg 1999;230:202 - 206.
  161. Gupta NC, Tamim WZ, Bishop HA. Is there any incremental value of routine lymph node sampling using mediastinoscopy and/or thoracotomy or open biopsy for management of lung cancer patients following whole body PET ? J Nucl Med 2000;41:76P.
  162. Gupta-Burt S, Marcus E, Coon J, et al. The role of positron-emission tomography (PET) in the assessment of pathologic response to neoadjuvant chemotherapy with doxorubicin and docetaxel in patients with locally advanced breast cancer . Eur J Cancer 1999;35:S316.
  163. Haase A, Lauer I, Meller B, Richter E, Baehre MH. Feasibility of detecting unknown primary tumors with gamma camera coincidence PET . J Nucl Med 2000;41:296P.
  164. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993;34:12 - 17.
  165. Haenggeli CA, Dulguerov P, Slosman D, et al. Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in early detection of residual tumor in oro-pharyngeal-laryngeal carcinoma [in German]. Schweiz Med Wochenschr. 2000;116.(suppl):8S - 11S.
  166. Hagberg RC, Segall GM, Stark P, Burdon TA, Pompili MF. Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography. Eur J Cardiothorac Surg 1997;12:92 - 97.
  167. Hain SF, O´Doherty MJ, Huddart RA, Leslie MD, Timothy AR, Harper PG. The value of FDG-PET in recurrent testicular carcinoma . J Nucl Med 1999;40:105P.
  168. Hain SF, O´Doherty MJ, Leslie MD, Timothy AR. Staging of testicular carcinoma with FDG-PET . J Nucl Med 1999;40:256P.
  169. Hain SF, O´Doherty MJ, Lucas JD, Smith MA. Fluorodeoxyglucose PET in the evaluation of amputations for soft tissue sarcoma. Nucl Med Commun 1999;20:845 - 848.
  170. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999;109:880 - 885.
  171. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990 - 995.
  172. Harms W, Bares R, Kamps H, Gronimus R, Boeckmann W, Jake G. Therapy control of metastatic testicular carcinoma with F18-DOG PET . J Nucl Med 1995;36:198P.
  173. Harrison J, Ali A, Bonomi P, Prinz R. The role of positron emission tomography in selecting patients with metastatic cancer for adrenalectomy. Am Surg 2000;66:432 - 437.
  174. Haseman MK, Reed NL, Rosenthal SA. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen positron emission tomography and biopsy correlation. Clin Nucl Med 1996;21:704 - 713.
  175. Hathaway PB, Mankoff DA, Maravilla KR, et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999;210:807 - 814.
  176. Heicappell R, Mueller-Mattheis V, Reinhardt M, et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-(18F)-2-deoxy-D-glucose. Eur Urol 1999;36:582 - 587.
  177. Heinz R, Ferris N, Lee EK, et al. MR and positron emission tomography in the diagnosis of surgically correctable temporal lobe epilepsy. Am J Neuroradiol 1994;15:1341 - 1348.
  178. Helveston W, Gilmore R, Roper S, et al. Intractable temporal lobe epilepsy: comparison of positron emission tomography with qualitative and quantitative MR. Am J Neuroradiol 1996;17:1515 - 1521.
  179. Henze M, Brix G, Knopp M, et al. Functional breast imaging: comparison of 18F-fluorodeoxyglucose (FDG) PET and pharmacokinetic MR mapping (DMRI) . J Nucl Med 2000;41:290P.
  180. Henze M, Mohammed A, Mier W, et al. Pretreatment studies of 18F-fluorodeoxyglucose (FDG), 123I-[alpha]-methlytyrosine (IMT) and 99mTc-sestamibi uptake in hypopharynx-larynx-carcinomas . J Nucl Med. 2000;41:142P.
  181. Herholz K, Perani D, Salmon E, et al. Comparability of FDG PET studies in probable Alzheimer´s disease. J Nucl Med 1993;34:1460 - 1466.
  182. Hicks RJ, Binns D, Kalff V, et al. The utility of flourine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) for restaging of non-small cell lung cancer (NSCLC): Analysis of management change and survival in 63 consecutive patients . J Nucl Med 2000;41:75P.
  183. Higashi K, Nishikawa T, Seki H, et al. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer. J Nucl Med 1998;39:9 - 15.
  184. Higashi K, Ueda Y, Kodama Y, et al. Comparison of 18F FDG PET and 201Tl SPECT in evaluation of pulmonary nodules . J Nucl Med 2000;41:297P.
  185. Higashi T, Sakahara H, Torizuka T, et al. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. J Nucl Med 1999;40:1424 - 1433.
  186. Hoda S, Ardakani N, Hawkins RA. Significance of PET-FDG in comparison with 131I WBS and serum Tg in detection of recurrent and metastatic papillary thyroid carcinoma . J Nucl Med 2000;41:312P.
  187. Hoffman J, Welsh-Bohmer K, Hanson M, et al. FDG-PET imaging in pathologically verified dementia. J Nucl Med 2000;41:1920 - 1928.
  188. Hoffman JM, Waskin HA, Schifter T, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993;34:567 - 575.
  189. Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999;10:1185 - 1189.
  190. Hoh C, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin´s disease and lymphoma. J Nucl Med 1997;38:343 - 348.
  191. Hoh CK, Chap L, Glaspy JA, Bui S, Czernin J, Phelps ME. Prognostic value of whole body FDG PET in breast cancer patients undergoing chemotherapy . J Nucl Med 1998;39:254P.
  192. Hoh CK, Figlin RA, Belldegrun A, et al. Evaluation of renal cell carcinoma with whole body FDG PET . J Nucl Med 1996;37:141P.
  193. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993;17:582 - 589.
  194. Hoh CK, Rosen PJ, Belldegrun A, Moon DH, Maddahi J, Phelps ME. Quantitative and whole-body FDG PET in the evaluation of suramin therapy in patients with metastatic prostate cancer . J Nucl Med 1996;37:267P.
  195. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764 - 771.
  196. Holopainen IE, Lundbom NM, Metsähonkala EL, et al. Temporal lobe pathology in epilepsy: proton magnetic resonance spectroscopy and positron emission tomography study. Pediatr Neurol 1997;16:98 - 104.
  197. Holthoff VA, Herholz K, Berthold F, et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 1993;72:1394 - 1403.
  198. Hölzer T, Herholz K, Jeske J, Heiss WD. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 1993;17:681 - 687.
  199. Hsueh EC, Gupta RK, Glass EC, Yee R, Qi K, Morton DL. Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J Am Coll Surg 1998;187:191 - 197.
  200. Hübner K, McDonald T, Niethammer J, Smith G, Gould H, Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using (2-[18F]FDG). Gynecol Oncol 1993;51:197 - 204.
  201. Hübner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images. Clin Nucl Med 1996;21:941 - 949.
  202. Hübner KF, Buonocore E, Singh SK, Gould HR, Cotten DW. Characterization of chest masses by FDG positron emission tomography. Clin Nucl Med. 1995;20:293 - 298.
  203. Hustinx R, Smith RJ, Benard F, Bhatnagar A, Alavi A. Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med 1999;26:1501 - 1509.
  204. Hwang KH, Park CH, Kim HC, Kim HS, Yoon SN, Kim S. Imaging of malignant lymphomas with 18F-FDG coincidence detection PET (CoDe-PET) . J Nucl Med 2000;41:278P.
  205. Imdahl A, Nitzsche E, Krautmann F, et al. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999;86:194 - 199.
  206. Imdahl A, Reinhardt MJ, Nitzsche EU, et al. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 2000;385:129 - 134. 10796051&;kyD[d]
  207. Inagaki K, Morita T, Fujii K, Kosaka N, Hara T. Mediastinal lymph node staging in non-small cell lung cancer using PET with C-11 choline and F-18 FDG . J Nucl Med 1999;40:59P - 60P.
  208. Inokuma T, Tamaki N, Torizuka T, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995;195:345 - 352.
  209. Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995;36:788 - 793.
  210. Inubushi M, Ishida Y, Fukuchi K, Fukushima K, Sasako K. Myocardial viability assessment using 18F FDG gated PET . J Nucl Med 2000;41:157P.
  211. Israel O, Yefremov N, Mor M, et al. 67Ga scintigraphy and 18F FDG coincidence imaging in the evaluation of lymphoma . J Nucl Med 2000;41:141P.
  212. Jacobson AF, Maisey MN, Fogelman I. Yield of FDG-PET scans for identifying active malignancy in patients with elevated tumour markers . J Nucl Med 1999;40:101P - 102P.
  213. Jacobson AF, Maisey MN, Fogelman I, Kuhn D. Yield of FDG-PET scanning as a routine follow-up exam in patients with malignancy . J Nucl Med 2000;41:304P.
  214. Jadvar H, Fischman AJ. Clinical impact of FDG PET on the management of patients with pancreatic carcinoma: comparison with CT and CA19-9 serology . J Nucl Med 1999;40:104P.
  215. Jadvar H, Johnson DL, Segall GM. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med 2000;25:48 - 51.
  216. Jadvar H, McDougall IR, Segall GM. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography. Nucl Med Commun 1998;19:547 - 554.
  217. Jansson T, Westlin JE, Ahlström H, Lilja A, Långström B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995;13:1470 - 1477.
  218. Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993;33:540 - 548.
  219. Jerusalem G, Beguin Y, Fasotte M, et al. Whole body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin´s disease and non-Hodgkin´s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429 - 433.
  220. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin´s lymphoma. Haematologica 2000;85:613 - 618.
  221. Jerusalem G, Warland V, Najjar F, et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin´s disease and non-Hodgkin´s lymphoma. Nucl Med Commun 1999;20:13 - 20.
  222. Kahn D, Follett KA, Bushnell DL, et al. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. AJR 1994;163:1459 - 1465.
  223. Kalff V, Hicks RJ, McManus M, et al. The clinical impact of PET scanning in patients with lung cancer: a prospective . J Nucl Med 1998;39:249P.
  224. Karlan BY, Hawkins R, Hoh C, et al. Whole-body positron emission tomography with 2-(18F)-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993;51:175 - 181.
  225. Kato T, Tsukamoto E, Shiga T, et al. Preliminary results of whole body FDG-PET in biliary carcinoma . J Nucl Med 2000;41:298P.
  226. Keogan MT, Lowe VJ, Baker ME, McDermott VG, Lyerly HK, Coleman RE. Local recurrence of rectal cancer: evaluation of F-18 fluorodeoxyglucose PET imaging. Abdom Imaging 1997;22:332 - 337.
  227. Kerrou K, Montravers F, Grahek D, Younsi N, de Beco V, Talbot JN. Follow-up of ovarian cancer using (18F)-FDG scan with a dual-head coincidence gamma camera (CDET) . J Nucl Med 2000;41:302P.
  228. Keyes JW Jr, Chen MY, Watson NE Jr, Greven KM, McGuirt WF, Williams DW III. FDG PET evaluation of head and neck cancer: value of imaging the thorax. Head Neck 2000;22:105 - 110.
  229. Kim DG, Kim CY, Paek SH, et al. Whole-body [18F]FDG PET in the management of metastatic brain tumours. Acta Neurochirurg 1998;140:665 - 684.
  230. Kim JH, Choi CW, Kim BG, et al. FDG-PET in patients with cervical cancer of uterus: experience in patients with clinically no evidence of disease . J Nucl Med 2000;41:300P.
  231. Kim S, Park CH, Han MH, et al. How useful is 18F-FDG coincidence detection positron emission tomography in the staging of lung cancer? J Nucl Med 2000;41:296P - 297P.
  232. Kincaid PK, El-Saden SM, Park SH, Goy BW. Cerebral gangliogliomas: preoperative grading using FDG-PET and 201Tl-SPECT [see comments]. Am J Neuroradiol 1998;19:801 - 806.
  233. Kluge R, Berr F, Schmidt F, et al. Value of 18F-FDG PET in detection and staging of perihilar cholangiocarcinoma . J Nucl Med 2000;41:36P.
  234. Klutmann S, Bohuslavizki KH, Buchert R, et al. Impact of 18F-FDG-PET in patients with cancer of unknown primary . J Nucl Med 1999;40:259P.
  235. Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 1996;109:982 - 988.
  236. Knuuti M, Saraste M, Nuutila P. Myocardial viability: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. Am Heart J 1994;127:785 - 796.
  237. Kole A, Plukker J, Nieweg O, Vaalburg W. Positron emission tomography for staging of gastroesophageal malignancy. Br J Cancer 1998;78:521 - 527.
  238. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82:1160 - 1166.
  239. Kole AC, Nieweg OE, Pruim J, et al. Whole-body PET with FDG: detection of unknown primary tumors . J Nucl Med 1995;36:57P.
  240. Kole AC, Nieweg OE, van Ginkel RJ, et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose. Ann Surg Oncol 1997;4:57 - 63.
  241. Kostakoglu L, Leonard JP, Coleman M, Kuji I, Vallabhajosula S, Goldsmith SJ. Evaluation of FDG-PET in the detection of bone marrow involvement in lymphoma . J Nucl Med 2000;41:71P.
  242. Kostakoglu L, Leonard JP, Coleman M, Kuji I, Vallabhajosula S, Goldsmith SJ. Comparison of FDG-PET and 67Ga SPECT in the staging of lymphoma . J Nucl Med 2000;41:118P.
  243. Kosuda S, Grossman HB, Kison PV, Wahl RL. Preliminary FDG-PET study in patients with bladder cancer . J Nucl Med 1996;37:260P.
  244. Kraemer DLA, Griebel ML, Lee N, Friedman AH, Radtke RA. Surgical outcome in patients with epilepsy with occult vascular malformations treated with lesionectomy. Epilepsia 1998;39:600 - 607.
  245. Kubik-Huch RA, Dörffler W, von Schulthess GK, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10:761 - 767.
  246. Kuehnel G, Rades D, Wildfang I, et al. Whole-body positron emission tomography (PET) with 18F-FDG in patients with cancer of unknown primary . J Nucl Med 2000;41:300P.
  247. Kunkel M, Kuffner HD, Reichert TE, Benz P, Förster GJ, Wagner W. (18F)-2-fluorodeoxyglucose PET. Prospects for secondary prevention of mouth cavity carcinoma [in German]. Mund Kiefer Gesichtschirurg 2000;4:105 - 110.
  248. Kurtaran A, Becherer A, Poetzi C, et al. Limited value of (18F)FDG-PET in localizing of recurrent/metastatic medullary thyroid carcinoma (MTC) . J Nucl Med 2000;41:308P.
  249. Kutlu CA, Pastorino U, Maisey M, Goldstraw P. Selective use of PET scan in the preoperative staging of NSCLC. Lung Cancer 1998;21:177 - 184.
  250. Lai DT, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with [18F] fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996;131:703 - 707.
  251. Lang O, Bihl H. Carcinoma of unknown primary (CUP): value of whole-body F-18-FDG-PET for detection of the primary tumor . J Nucl Med 1999;40:259P.
  252. Lang O, Brouwers AH, Mergenthaler HG, Doerr U, Bihl H. Value of whole-body 18F-FDG-PET in metastatic renal cell carcinoma: correlation with tumor aggressiveness ? J Nucl Med 2000;41:117P.
  253. Lang O, Doerr U, Merkle P, Bihl H. Whole-body 18F-FDG-PET in patients with suspected recurrence of colorectal cancer: a comparison with CT and MRI . J Nucl Med 2000;41:35P.
  254. Lang O, Doerr U, Schneider K, Hagen R, Bihl H. Cervical lymph node staging in patients with head and neck cancer: a comparison between 18F-FDG-PET and ultrasound . J Nucl Med 2000;41:32P.
  255. Laningham FH, Smith GT, Hanna WT, Hubner KF. The impact of whole body FDG PET on the management of patients with malignant melanoma . Clin Positron Imaging 1998;1:262.
  256. Lapela M, Eigtved A, Jyrkkiö S, et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 2000;36:858 - 867.
  257. Lapela M, Grénman R, Kurki T, et al. Head and neck cancer: detection of recurrence with PET and 2-Figure F-18fluoro-2-deoxy-D-glucose. Radiology 1995;197:205 - 211.
  258. Lassen U, Daugaard G, Eigtved A, Damgaard K, Friberg L. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999;35:1076 - 1082.
  259. Leiderman DB, Balish M, Sato S, et al. Comparison of PET measurements of cerebral blood flow and glucose metabolism for the localization of human epileptic foci. Epilepsy Res 1992;13:153 - 157.
  260. Lenzo NP, Shulkin B, Castle VP, Hutchinson RJ. FDG PET in childhood soft tissue sarcoma . J Nucl Med 2000;41:96P.
  261. Lewis P, Griffin S, Marsden P, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344:1265 - 1266.
  262. Li PY, Mozley PD, Zhuang HM, et al. Effectiveness of FDG PET in the detection of recurrent squamous cell carcinoma of the head and neck . J Nucl Med 2000;41:32P.
  263. Lin PC, Chu J, Pocock N. 18F fluorodeoxyglucose imaging with coincidence dual-head gamma camera (hybrid FDG-PET) for staging of lymphoma: comparison with 67Ga scintigraphy . J Nucl Med 2000;41:118P.
  264. Lin PC, Chu J, Pocock N, Quach T, Sorensen B. F-18 FDG imaging with coincidence dual-head gamma camera (co-PET) in staging of lymphoma: comparison with CT and gallium scans . J Nucl Med 1999;40:62P.
  265. Lindholm P, Leskinen-Kallio S, Minn H, et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. J Nucl Med 1993;34:1711 - 1716.
  266. Liu RS, Chu LS, Lee CH, et al. Limited usefulness of (11C)acetate whole body PET in patients with thyroid cancer . J Nucl Med 2000;41:310P.
  267. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O´Doherty MJ. A six-hour study of soft tissue masses using FDG PET . J Nucl Med 1998;39:255P.
  268. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O´Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22 - 30.
  269. Lonneux M, Borbath I, Bausart R, Pauwels S. The role of PET-18FDG in detecting distant recurrence of breast cancer . J Nucl Med 1999;40:250P.
  270. Lonneux M, Delval D, Bausart R, et al. Can dual-headed 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer. Nucl Med Commun 1998;19:1047 - 1054.
  271. Lowe V, Boyd J, Dunphy F, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000;18:651 - 658.
  272. Lowe V, Dunphy F, Varvares M, et al. Evaluation of chemotherapeutic response in patients with advanced head and neck cancer using Figure F-18 fluorodeoxyglucose positron emission tomography. Head Neck 1997;19:666 - 674.
  273. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075 - 1084.
  274. Lowe VJ, Kim H, Boyd JH, Eisenbeis JF, Dunphy FR, Fletcher JW. Primary and recurrent early stage laryngeal cancer: preliminary results of 2-[fluorine 18]fluoro-2-deoxy-D-glucose PET imaging. Radiology 1999;212:799 - 802.
  275. Lowe VJ, Naunheim KS, Dunphy FR, Kim HJ, Fletcher JW. Evaluation of diagnostic testing discrepancies in the management of lung cancer: a review incorporating (F-18)FDG-PET imaging . J Nucl Med 1998;39:248P.
  276. Lucas JD, O´Doherty MJ, Cronin BF, et al. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 1999;86:550 - 556.
  277. Lucas JD, O´Doherty MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg. [British volume] 1998;80:441 - 447.
  278. Lucignani G, Paolini G, Landoni C. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxybutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992;19:874 - 881.
  279. Lucignani G, Tassi L, Fazio F, et al. Double-blind stereo-EEG and FDG PET study in severe partial epilepsies: are the electric and metabolic findings related? Eur J Nucl Med 1996;23:1498 - 1507.
  280. Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999;68:1133 - 1137.
  281. Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 1997;64:765 - 769.
  282. Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998;16:1770 - 1776.
  283. Maes A, Borgers M, Flameng W. Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT: correlation with histologic and positron emission tomographic studies and functional follow up. J Am Coll Cardiol 1997;29:62 - 68.
  284. Magnani P, Carretta A, Rizzo G, et al. FDG/PET and spiral CT image fusion for mediastinal lymph node assessment of non-small cell lung cancer patients. J Cardiovasc Surg 1999;40:741 - 748.
  285. Maisey M, Wahl R, Barrington S. Atlas of Clinical Positron Emission Tomography London, UK: Arnold, Hodder Headline Group; 1999.
  286. Maisey NR, Hill ME, Webb A, et al. Are 18-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000;36:200 - 206.
  287. Maldonado A, Sancho F, Calvo F, et al. The role of FDG-PET in diagnosing suspected tumor recurrence based on increased levels of plasma markers . Clin Positron Imaging 1998;1:246.
  288. Manolidis S, Donald PJ, Volk P, Pounds TR. The use of positron emission tomography scanning in occult and recurrent head and neck cancer. Acta Otolaryngol 1998;534.(suppl):1 - 11.
  289. Markand ON, Salanova V, Worth R, Park HM, Wellman HN. Comparative study of interictal PET and ictal SPECT in complex partial seizures. Acta Neurol Scand. 1997;95:129 - 136.
  290. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803 - 809.
  291. Martin L, Fazel A, Burton F, Fletcher JW. Performance of dedicated, non-attenuation corrected FDG-PET in diagnosis and staging of pancreatic cancer (PCa) . J Nucl Med 2000;41:35P - 36P.
  292. Martinez-Lazaro R, Cortes-Blanco A, Zhuang HM, Alavi AA. Diagnostic performance of whole-body FDG-PET and CT imaging in malignant lymphomas . J Nucl Med 2000;41:277P.
  293. Matthies A, Smith RJ, Cuchiara AJ, Alavi AA. Dual time point 18FDG-PET imaging for the differentiation between benign and malignant pulmonary nodules . J Nucl Med 2000;41:293P.
  294. Melchior SW, Fichtner J, Jones J, et al. Changes in fluorodeoxyglucose (FDG) uptake measured by positron emission tomography (PET) in prostate cancer (CaP) patients following androgen withdrawal . J Urol 1999;161:297.
  295. Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer. Comparison with computed tomography. Clin Nucl Med. 2000;25:882 - 887.
  296. Menda Y, Bushnell DL, Madsen MT, Kernstine KH, McLaughlin K, Hichwa RD. Retrospective analysis of standardized uptake values of lung masses with 18F FDG PET . J Nucl Med 2000;41:295P.
  297. Meta J, Valk P, Ariannejad M, et al. Impact of FDG-PET on management of patients with colorectal cancer . J Nucl Med 2000;41:299P.
  298. Mielke R, Heiss WD. Positron emission tomography for diagnosis of Alzheimer´s disease and vascular dementia. J Neural Transm 1998;53:237 - 250.
  299. Mielke R, Pietrzyk U, Jacobs A, et al. HMPAO SPET and FDG PET in Alzheimer´s disease and vascular dementia: comparison of perfusion and metabolic pattern [see comments]. Eur J Nucl Med 1994;21:1052 - 1060.
  300. Mielke R, Schroeder R, Fink GR, Kessler J, Herholz K, Heiss WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer´s disease. Acta Neuropathol 1996;91:174 - 179.
  301. Mikhaeel NG, Timothy AR, Hain SF, O´Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000;11.(suppl 1):147 - 150.
  302. Montravers F, Grahek D, Kerrou K, de Beco V, Younsi N, Talbot JN. Comparison of FDG scan on a dual-head coincidence gamma camera (CDET) and conventional imaging for the diagnosis of recurrence of colorectal cancer . J Nucl Med 2000;41:300P.
  303. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-Figure F-18fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997;203:795 - 800.
  304. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475 - 481.
  305. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999;40:1407 - 1413.
  306. Moon D, Maddahi J, Silverman D, Glaspy J, Phelps M, Hoh C. Accuracy of whole body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431 - 435.
  307. Mruck S, Baum RP, Rinne D, Hoer G. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics. Anticancer Res 1999;19:2685 - 2690.
  308. Mueller SP, Goerges R, Brandt-Mainz K, Bockisch A. The role of FDG-PET and 201Tl imaging as a preoperative diagnostic tool in recurrent Hürthle cell carcinoma of the thyroid . J Nucl Med 2000;41:306P.
  309. Mukahira K, Oguni H, Awaya Y, et al. Study on surgical treatment of intractable childhood epilepsy. Brain Dev 1998;20:154 - 164.
  310. Musholt TJ, Musholt PB, Dehdashti F, Moley JF. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery (St. Louis) 1997;122:1049 - 1061.
  311. Myers LL, Wax MK. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer. J Otolaryngol 1998;27:342 - 347.
  312. Nakamoto Y, Higashi T, Sakahara H, et al. Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiol 1999;54:248 - 252.
  313. Nakamoto Y, Saga T, Ishimori T, et al. Clinical contribution of FDG-PET for follow-up patients with gynecological malignancies . J Nucl Med 2000;41:301P.
  314. Nettelbladt OS, Sundin AE, Valind SO, et al. Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum. J Nucl Med 1998;39:640 - 647.
  315. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-Figure F-18-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111 - 116.
  316. Nguyen A, Akhurst T, Larson S, Coit D, Brady M. PET Scanning with 18F2-fluoro-2-deoxy-D-glucose(FDG) in patients with melanoma: benefits and limitations. Clin Positron Imaging 1999;2:93 - 98.
  317. Nieweg O, Kim E, Wong W, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71:3920 - 3925.
  318. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257 - 261.
  319. Nitzsche EU, Hoh CK, Dalbohm NM, et al. Whole body positron emission tomography in breast cancer [in German]. Rofo Fortschr Geb Rontgenstr 1993;158:293 - 298.
  320. Nitzsche EU, Simon GH, Krautmann F, et al. Is FDG PET indicated when cancer disease of the pancreas is diagnosed based on CT ? J Nucl Med 1997;38:144P.
  321. Noh D, Yun I, Kim J, et al. Diagnostic value of positron emission tomography for detecting breast cancer. World J Surg. 1998;22:223 - 228.
  322. Noh DY, Yun IJ, Kang HS, et al. Detection of cancer in augmented breasts by positron emission tomography. Euro J Surg. 1999;165:847 - 851.
  323. Nowak B, Di Martino E, Jänicke S, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 1999;38:312 - 318.
  324. Nunez RF, Yeung HW, Macapinlac HA, Larson SM. Does post radiation therapy change in the lung affect the accuracy of FDG-PET in the evaluation of tumor recurrence in lung cancer ? J Nucl Med 1999;40:234P.
  325. Nuutinen J, Leskinen S, Elomaa I, et al. FDG-PET imaging of residual testicular cancer after chemotherapy . J Nucl Med 1996;37:256P.
  326. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613 - 620.
  327. Orino K, Kawamura M, Hatazawa J, Suzuki I, Sazawa Y. Efficacy of F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scans in diagnosis of pulmonary nodules [in Japanese]. Jpn J Thorac Cardiovasc Surg 1998;46:1267 - 1274.
  328. Oriuchi N, Ichikawa A, Koyama K, et al. Clinical significance of L-(3-18F)- alpha-methyl tyrosine PET studies in intracranial and intrathoracic tumor: a comparative study with 18F-FDG PET . J Nucl Med 2000;41:291P - 292P.
  329. Oyama N, Akino H, Suzuki Y, et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999;29:623 - 629.
  330. Oyama N, Akino H, Suzuki Y, et al. FDG-PET for evaluating the effectiveness of endocrine therapy for prostate cancer . J Nucl Med 1999;40:256P - 257P.
  331. Oyen WJ, Neeleman N, Ruers TJ, Jager GJ, Wobbes T, Corstens FH. FDG-PET in metastasized colorectal carcinoma . J Nucl Med. 2000;41:35P.
  332. Pai M, Park CH, Suh JH, Koh JH. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer. Clin Nucl Med 1999;24:495 - 500.
  333. Palmedo H, Bender H, Grünwald F, Mallmann P, Krebs D, Biersack H. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumors. Eur J Nucl Med 1997;24:1138 - 1145.
  334. Paquet P, Henry F, Belhocine T, et al. An appraisal of 18-fluorodeoxyglucose positron emission tomography for melanoma staging. Dermatology 2000;200:167 - 169.
  335. Patz EF Jr, Lowe VJ, Goodman PC, Herndon J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 1995;108:1617 - 1621.
  336. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487 - 490.
  337. Patz EF, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-(F-18)-12-deoxy-D-glucose. Radiology 1994;191:379 - 382.
  338. Paulus P, Sambon A, Vivegnis D, et al. 18FDG PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients. Laryngoscope 1998;108:1578 - 1583.
  339. Pawlik G, Holthoff VA, Kessler J, et al. Positron emission tomography findings relevant to neurosurgery for epilepsy. Acta Neurochirurg 1990;50. (suppl):84 - 87.
  340. Peterson LM, Graham MM, Hayward RM, Yeung RS, Hansen PD. FDG PET identify residual or recurrent disease following local ablation of liver metastases . J Nucl Med 2000;41:287P.
  341. Präuer HW, Weber WA, Römer W, Treumann T, Ziegler SI, Schwaiger M. Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules. Br J Surg 1998;85:1506 - 1511.
  342. Que TH, Plukker JT, Vaalburg W. Staging of gastroesophageal cancer with PET using 11C choline and 18F FDG . J Nucl Med 2000;41:141P.
  343. Raja S, Fernandez-Vicioso E, Suh JH, et al. Brain tumor recurrence versus radiation necrosis: role of Tc